Stock RIGL RIGEL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Rigel Pharmaceuticals, Inc.

Equities

RIGL

US7665596034

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
1.125 USD -1.32% Intraday chart for Rigel Pharmaceuticals, Inc. +1.35% -22.41%
Apr. 12 Rigel Pharmaceuticals, Inc. Enters into Amendment No. 4 to that Certain Credit and Security Agreement CI
Mar. 12 Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Citigroup Adjusts Rigel Pharmaceuticals' Price Target to $4 From $3, Maintains Buy Rating
MT
B. Riley Lifts Rigel Pharmaceuticals' PT to $1.75 From $1.25 After Announced Purchase of US Rights to Gavreto From Blueprint Medicines; Keeps Neutral Rating
MT
B. Riley Trims Rigel Pharmaceuticals' PT to $1.25 From $1.75, Lowers Peak Sales Estimate for Rezlidhia; Maintains Neutral Rating
MT
Piper Sandler Assumes Neutral Rating on Rigel Pharmaceuticals With $2 Price Target
MT
Citigroup Adjusts Price Target on Rigel Pharmaceuticals to $3 From $2, Keeps Buy Rating
MT
Health Care Up as Rate Fears Weigh -- Health Care Roundup
DJ
Citigroup Upgrades Rigel Pharmaceuticals to Buy From Neutral, Raises Price Target to $2 From $1.50
MT
HC Wainwright Adjusts Rigel Pharmaceuticals' Price Target to $15 from $7, Keeps Buy Rating
MT
Piper Sandler Adjusts Price Target on Rigel Pharmaceuticals to $2 From $1, Maintains Neutral Rating
MT
Cantor Fitzgerald Raises Rigel Pharmaceuticals Price Target to $2 From $1, Maintains Neutral Rating
MT
BMO Lowers Rigel Pharmaceuticals' Price Target to $3 From $7, Maintains Outperform Rating
MT
B. Riley Lowers Rigel Pharmaceuticals' Price Target to $1.25 from $4 After Disappointing Trial Data on Fostamatinib, Keeps Neutral Rating
MT
Citigroup Downgrades Rigel Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $0.80 From $7
MT
Piper Sandler Cuts Rigel Pharmaceuticals to Neutral From Overweight, Price Target to $1 From $7
MT
Jefferies Lowers Rigel Pharmaceuticals to Hold From Buy, Price Target to $1 From $8
MT
HC Wainwright Adjusts Rigel Pharmaceuticals' Price Target to $7 from $11, Keeps Buy Rating
MT
Cantor Fitzgerald Downgrades Rigel Pharmaceuticals to Neutral from Overweight
MT
B. Riley Initiates Rigel Pharmaceuticals at Neutral with $4 Price Target, Notes Hidden Risks in Phase III Protocol for Warm Autoimmune Hemolytic Anemia
MT
RIGEL PHARMACEUTICALS : JPMorgan Downgrades Rigel Pharmaceuticals to Neutral From Overweight
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RIGL Stock
  4. News Rigel Pharmaceuticals, Inc.
  5. Analyst Reco.